#United States #Indianapolis #cancer therapies #Actinium-225 #Cardinal Health

Cardinal Health Expands Actinium-225 Production Capacity

Cardinal Health, a leader in pharmaceutical distribution and manufacturing, has recently unveiled plans to significantly enhance its production capacity for Actinium-225 (Ac-225). This strategic move is aimed at supporting the escalating demand for innovative cancer therapies, particularly those that utilize targeted alpha particle therapy. The expansion will take place at their Center for Theranostics Advancement (CTA) located in Indianapolis, Indiana.

Ac-225 is an alpha-emitting radionuclide that can be attached to various molecules designed specifically to target cancerous cells. This technology is part of a promising new class of treatments for various cancers, including prostate cancer, neuroendocrine tumors, breast cancer, colon cancer, melanoma, and lymphoma. Despite the potential of Ac-225 therapies, the progress in clinical settings has been hampered by a limited supply of this crucial material.

Since the company's announcement of routine global production in late 2024, Cardinal Health has significantly ramped up its weekly output, quadrupling the production capacity in response to the growing global needs for targeted alpha therapies. The recent investment in a new high-capacity production line is expected to substantially increase the available supply of cGMP-compliant Ac-225 for both investigational therapeutic drug development and future commercial manufacturing of these innovative therapies.

Shane Thrasher, Vice President of Radiopharmaceutical Manufacturing at Cardinal Health Nuclear Precision Health Solutions, emphasized the importance of this expansion. He stated that enhancing Ac-225 production is a critical advancement for both the industry and for patients who rely on these therapies.